Schering-Plough market

Total sales of prescription bronchodHators and antiasthma products in 1989 were approximately 1.2 and 3.3 bHHon in the North American and world markets, respectively (166). The three largest shares of the world market were held by Glaxo Holdings pic, Schering-Plough Corporation, and Boehringer Ingelheim Corporation. 

Common side effects noted include injection site reactions, weakness, dizziness, weight loss and flu-like symptoms, with depression being the most common reason for treatment discontinuation. ViraferonPeg is manufactured and marketed by Schering Plough. 

Commercial costs for bulk quantities. Data from Dr. P. Savle, Schering-Plough, IQ 07, and Chemical Market Reporter. 

In this spirit, it is pertinent to recount some of the work done under Arapahoe Chemicals/Syntex, Glaxo, Bristol-Myers, and Schering-Plough auspices, much of which illustrates the influence of competition, patent portfolios, business, new discoveries, safety, the environment, and marketing, some of which shows that compelling opportunities can resurrect chemical transformations previously cast off as unworkable or commercially uninteresting. 

Figures from Chemical Marketing Reporter, April 2007, and Dr. Prashant Savle, Schering-Plough. Bracketed figure assumes that four hydrogens are available.

Companies with one blockbuster brand or R D budget of > 1 billion are listed. Marketing joint ventures like Takeda-Abbott Pharmaceutical, Merck-Schering Plough are not listed. 

The fluoroquinolones are second-generation antibacterials. Ciprofloxacin (CIPRO, Bayer AG), moxifloxacin (AVELOX, developed by Bayer AG and marketed in the United States by Schering-Plough Corp.), and levofloxacin (LEVAQUIN, Ortho-McNeil-Janssen Pharmaceuticals, Inc.) are examples of this group. All are antibiotics used to treat or prevent certain infections caused by bacteria. Ciprofloxacin is also used to treat or prevent anthrax in people who may have been exposed to anthrax germs in the air. Similarly,... 

---